Document Detail


Cholecystokinin mediation of colonic absorption via peptide YY: foregut-hindgut axis.
MedLine Citation:
PMID:  8661821     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Peptide YY (PYY), a 36-amino-acid polypeptide, is found in abundance in the colon, a region where its physiologic roles are unknown. Previous studies have revealed a substantial increase in plasma PYY after cholecystokinin (CCK) administration. PYY is released from the hindgut in response to a meal and inhibits CCK release. In this study we evaluated the effects of CCK and PYY on intestinal absorption of water and electrolytes. Colonic, ileal, or jejunal Thiry-Vella fistulas (TVFs) were created in 12 dogs, and intestinal continuity was reestablished. The TVFs were perfused with an isotonic buffer solution containing [14C] PEG as a volume marker. Electrolyte and water transport were measured every 15 minutes, and plasma PYY and CCK levels were measured by radioimmunoassay. Group 1 dogs received an intravenous bolus of MK329, a specific CCK receptor antagonist, at 20 nmol/kg after a standard mixed meal; group 2 colonic TVF dogs received a meal and an intravenous bolus of PYY polyclonal antibody at 1 mg/kg. Postprandially, all three regions of the bowel became significantly proabsorptive for water, sodium, and chloride. In the colon postprandial absorption was abolished by MK329 starting 60 minutes after a meal, whereas specific CCK receptor blockade blunted ileal absorption. CCK receptor blockade did not affect postprandial absorption in the jejunum. Postprandial PYY levels did not rise in MK329-treated animals. PYY antibody reduced colonic absorption during the postprandial phase. Reduction of meal-induced colonic absorption and PYY release by MK329 in awake dogs suggests an important foregut-hindgut hormonal feedback loop. Foregut-derived CCK stimulates hindgut PYY release, which in turn stimulates colonic absorption while inhibiting further CCK release.
Authors:
C D Liu; O J Hines; T R Newton; T E Adrian; M J Zinner; S W Ashley; D W McFadden
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  World journal of surgery     Volume:  20     ISSN:  0364-2313     ISO Abbreviation:  World J Surg     Publication Date:  1996 Feb 
Date Detail:
Created Date:  1996-12-05     Completed Date:  1996-12-05     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7704052     Medline TA:  World J Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  221-7     Citation Subset:  IM    
Affiliation:
Department of Surgery, UCLA Center for Health Sciences and Sepulveda VA Medical Center, 72-215 CHS, 10833 LeConte Avenue, Los Angeles, California 90024, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Benzodiazepinones / pharmacology
Buffers
Carbon Radioisotopes / diagnostic use
Chlorides / pharmacokinetics
Cholecystokinin / analysis,  blood,  pharmacology*
Colon / drug effects*,  metabolism
Devazepide
Digestion
Dogs
Electrolytes / pharmacokinetics
Feedback / drug effects
Female
Gastrointestinal Hormones / blood,  pharmacology*
Hormone Antagonists / pharmacology
Ileum / drug effects,  metabolism
Intestinal Absorption / drug effects*
Isotonic Solutions
Jejunum / drug effects,  metabolism
Peptide YY
Peptides / blood,  pharmacology*
Receptors, Cholecystokinin / analysis
Sodium / pharmacokinetics
Water / metabolism
Grant Support
ID/Acronym/Agency:
R01-DK-39879/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Benzodiazepinones; 0/Buffers; 0/Carbon Radioisotopes; 0/Chlorides; 0/Electrolytes; 0/Gastrointestinal Hormones; 0/Hormone Antagonists; 0/Isotonic Solutions; 0/Peptides; 0/Receptors, Cholecystokinin; 103420-77-5/Devazepide; 106388-42-5/Peptide YY; 7440-23-5/Sodium; 7732-18-5/Water; 9011-97-6/Cholecystokinin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Characteristic histologic features of human hepatocellular carcinoma with mutant p53 protein.
Next Document:  Enhanced expression of manganese superoxide dismutase mRNA and increased TNFalpha mRNA expression by...